Liberation Labs recently broke ground on its first commercial-scale, purpose-built, precision fermentation biomanufacturing facility in Richmond, Ind. The facility, which will have a capacity of 600,000 liters with a fully dedicated downstream process (DSP), will produce bio-based proteins and other building block ingredients at a scale and cost that will fill a pressing need among both new and established consumer packaged goods companies and other industrial manufacturers.
Liberation Labs’ approach will help overcome the two biggest challenges facing the industry today: cost and quality. By producing bio-based proteins in a purpose-built facility and at scale in the U.S instead of repurposed facilities overseas, Liberation Labs will reduce cost, which will help customers make the end product cost-competitive. Commercial production is expected by the end of 2024.